Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Two People Awarded $9 Mln Each In Accutane Case

6/30/2012 11:34 PM ET

A New Jersey jury on Friday awarded $9 million each to two people who took the anti-acne drug Accutane, made by Hoffmann-La Roche (RHHBY.PK), and developed bowel disease. Accutane causes inflammatory bowel disease in some individuals.

This was the eighth Accutane case to go to trial in the U.S. To date, plaintiffs have won over $78 million in verdicts against Roche.

The trial lasted almost two months. The jury turned back the claims of two other clients as it found that although Roche failed to warn their prescribing physicians of the dangers of Accutane, they would have been prescribed and taken Accutane anyway.

Click here to receive FREE breaking news email alerts for Roche Holding AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Design software maker Autodesk, Inc. (ADSK) Thursday reported a 30 percent decline in earnings from last year, hurt by lower revenue and weaker margins. The company's quarterly earnings per share, excluding items, came in below analysts' expectations as did its quarterly revenue. At the same time,... Struggling PC maker Dell Inc. said Thursday after the markets closed that its first quarter profit dropped 79% from last year, as revenue declined and margins deteriorated amid sluggish demand for personal computers. The company's quarterly earnings per share, excluding items, also came in way below analysts' expectations, but its quarterly revenue beat analysts' forecast. Cisco Systems, Inc., the world's largest computer networking gear maker, said Wednesday after the markets closed that its third quarter profit rose 14.5% from last year, helped by higher sales and a tax benefit. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly sales.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.